The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

NARecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

March 31, 2029

Conditions
Ischemic Heart Disease (IHD)Cardiac Magnetic Resonance ImagingMyocardial Blood Flow
Interventions
DIAGNOSTIC_TEST

Quantitative Myocardial Blood Flow Evaluation

The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.

DIAGNOSTIC_TEST

Qualitative Myocardial Blood Flow Evaluation

The perfusion sequence will not produce additional quantitative perfusion maps.

DRUG

Gadavist

Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).

DRUG

Vasodilator

All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).

DIAGNOSTIC_TEST

Blood draw for the laboratory assessment

A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT06854458 - The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study | Biotech Hunter | Biotech Hunter